U.S. Basic Materials Stock News

Cogent Biosciences (COGT) is in focus after sharing new preclinical data on its KRAS and ErbB2 drug candidates at the AACR 2026 meeting in San Diego, highlighting selectivity, activity and safety signals. See our latest analysis for Cogent Biosciences. The AACR presentations land at a time when Cogent Biosciences’ share price, now at $36.81, has seen a 1 day share price return of 1.85% and a year to date share price return of 5.96%. The 1 year total shareholder return is around 7x, pointing...

Recent performance snapshot for Appian Appian (APPN) has drawn investor attention after recent trading, with the share price last closing at US$22.15. The stock shows a 2.5% move over the past day and 1.9% over the past week. See our latest analysis for Appian. That recent 1-day share price return of 2.5% and 7-day gain of 1.9% comes after a 90-day share price return of 25.9% decline and a 1-year total shareholder return of 28.5% decline, suggesting weak longer term momentum despite the...

Why Magnite’s new client deals matter for investors Magnite (MGNI) has just expanded its role with Hearst News as a preferred partner for high impact web and CTV ads, and it is also deepening ties with AMC Global Media on programmatic TV buying. These agreements focus on helping advertisers reach viewers across streaming, mobile, and web through formats such as CTV pause ads, exit intent placements, and unified access to AMC’s linear and streaming inventory. See our latest analysis for...

Amphenol (APH) is in focus after analysts raised earnings forecasts and highlighted its role as a high-margin supplier to AI-driven data centers, along with recent acquisitions that broaden its exposure to connectivity markets. See our latest analysis for Amphenol. The recent 21.11% 1 month share price return, alongside a 98.70% 1 year total shareholder return, points to strong momentum as investors respond to earnings optimism, AI data center exposure, and recent connectivity...

Vertiv Holdings Co recently reported first-quarter 2026 results, with revenue rising to US$2,649.5 million and net income to US$390.1 million, and issued higher second-quarter and full-year 2026 guidance, including expected net sales of up to US$14.00 billion and diluted EPS of up to US$5.70. The combination of strong earnings, improved margins, higher guidance, and a strengthened balance sheet has reinforced Vertiv’s position in fast-growing AI data center infrastructure and boosted analyst...

What triggered the latest move in CSW Industrials (CSW)? CSW Industrials (CSW) recently reported quarterly results with revenue up 20.3% year on year but 6% below analyst expectations, and adjusted operating income also missing estimates, pressuring the share price. See our latest analysis for CSW Industrials. At a share price of US$296.18, CSW Industrials has a 1 month share price return of 12.23%, while its 1 year total shareholder return of 4.53% decline contrasts with a very large 3 year...

In late April 2026, Herc Holdings drew investor attention after United Rentals reported strong first-quarter results, which lifted sentiment across the equipment rental industry and focused expectations on Herc’s upcoming earnings release. The key insight is that upbeat signals from a major competitor can quickly reshape perceptions of Herc’s near-term operating backdrop, even without new company-specific disclosures. We’ll now examine how stronger peer results, hinting at firmer end-market...

SoundHound AI triggered overview SoundHound AI (SOUN) is back on many investors’ screens after recent trading, with the share price closing at US$8.19 and showing mixed short term performance across the past week, month, and past 3 months. See our latest analysis for SoundHound AI. The recent 1 day share price return of 4.73% and 30 day share price return of 38.81% contrast with a year to date share price return of 22.74% and a 3 year total shareholder return above 3x. This suggests long term...

Booz Allen Hamilton recently disclosed that its venture arm, Booz Allen Ventures, invested in NODA AI, an autonomy orchestration firm that helps military operators coordinate heterogeneous, multi‑domain autonomous systems, aligning with the Department of War’s US$55.00 billion funding plan for autonomous capabilities. This move highlights how Booz Allen is plugging into the integration layer of defense autonomy, where orchestration technology could become a critical enabler for future...

Event context and recent performance snapshot GDS Holdings (NasdaqGM:GDS) has been drawing attention after a period of mixed share performance, with a gain of 11.6% over the past month and a 5.1% decline over the past 3 months. See our latest analysis for GDS Holdings. At a share price of US$45.08, GDS Holdings has seen short term momentum firm up with a 4.23% 1 day and 11.58% 30 day share price return. The 1 year total shareholder return of 92.81% and 3 year total shareholder return of...

Broadcom’s recent announcements include an expanded Google Cloud collaboration on the Cloud Network Insights observability service, a new VMware Tanzu Platform agent runtime for autonomous AI applications, and a multi-year, multi-generation AI infrastructure partnership with Meta extending through 2029. Together, these moves deepen Broadcom’s role at the center of hyperscale AI data centers and secure AI operations, potentially reinforcing demand visibility across both its custom AI silicon...

Alarm.com Holdings (ALRM) recently rolled out upgrades to its Universal Communicator, adding Smart Connector features, Verizon LTE support, and new firmware designed to simplify legacy alarm panel upgrades for homes and businesses. See our latest analysis for Alarm.com Holdings. Despite the product rollout, Alarm.com’s recent share price return has been mixed, with a 1 day share price return of 2.92% and a 30 day share price return of 5.27%. However, the year to date share price return of...

How Afya stock has been trading Afya (NasdaqGS:AFYA) has been under pressure recently, with the share price showing a 2.6% decline over the past day and double digit negative returns over the past week, month, past 3 months and year. Year to date, the stock is also in negative territory, while the 3 year total return remains positive. This mix of shorter term weakness and longer term gains sets the backdrop for assessing what the current price might already reflect. At the last close of...

Trex Company, a leading maker of sustainable wood-alternative decking and railing, was recently named one of America’s Climate Leaders 2026 by USA Today, recognizing its tangible progress in cutting its carbon footprint and advancing climate action. This designation highlights Trex’s extensive use of recycled and reclaimed materials and its role as one of North America’s largest recyclers of polyethylene film, potentially reinforcing its appeal to environmentally focused customers and...

Citi downgrade puts Bio-Rad Laboratories (BIO) under closer scrutiny Citigroup’s move to cut Bio-Rad Laboratories (BIO) to Neutral and lower its outlook on the stock has refocused attention on the company’s process chromatography margins and diagnostics exposure to China. See our latest analysis for Bio-Rad Laboratories. Bio-Rad’s 8.46% one-month share price return contrasts with a 5.71% year-to-date share price decline. The one-year total shareholder return of 19.85% also sits against a...

Why Pitney Bowes raised its 2026 revenue outlook Pitney Bowes (PBI) recently raised its full year 2026 revenue guidance to a range of US$1,800 million to US$1,860 million, up from a prior range that started at US$1,760 million. This adjustment, together with recent upward earnings estimate revisions and the absence of downward changes, has put fresh attention on how the stock’s current valuation lines up with those higher expectations. See our latest analysis for Pitney Bowes. The raised 2026...

Neurocrine Biosciences (NBIX) is back in focus after new two year Phase 3 CAHtalyst Adult data for CRENESSITY in classic congenital adrenal hyperplasia, highlighting sustained glucocorticoid reductions and a clean safety profile. See our latest analysis for Neurocrine Biosciences. At a share price of $127.68, Neurocrine Biosciences has seen a 1 year total shareholder return of 19.63%, while its year to date share price return of 9.19% points to fading short term momentum following recent...

PennyMac Mortgage Investment Trust (PMT) is back in focus after partnering with PennyMac Financial Services on the new Welcome Home: Athlete Mortgage Program for Team USA athletes, spotlighting its role in specialized residential mortgage financing. See our latest analysis for PennyMac Mortgage Investment Trust. While the Welcome Home program has put PennyMac Mortgage Investment Trust back on investors’ radar, the share price at US$12.12 reflects mixed momentum, with a 30 day share price...

What PROG Holdings' Recent Share Performance Tells You With no single headline event driving PROG Holdings (PRG) today, attention turns to how the stock has been trading recently and how that lines up with the company’s current fundamentals. See our latest analysis for PROG Holdings. Recent trading has been mixed, with a 10.24% 1 month share price return alongside a 5.73% 3 month share price decline, while the 1 year total shareholder return of 24.45% points to stronger longer term...

BlackLine (BL) has drawn investor attention after a sharp share price pullback, with the stock down about 15% over the past month and roughly 44% over the past 3 months. See our latest analysis for BlackLine. At a share price of $30.64, BlackLine’s recent 30 day share price return of 15% decline and 90 day share price return of 43.8% decline contrast with a 1 year total shareholder return of 35.1% decline. This pattern suggests momentum has been fading and risk perceptions may have...

If you are wondering whether Kinsale Capital Group at around US$345 per share looks like value or a value trap, the next sections break down what the current price might be implying. The stock has been volatile recently, with a 4.4% decline over the last 7 days, a 5.4% gain over 30 days, and returns of 12.1% decline year to date and 17.7% decline over the last year, set against 6.1% and 100.1% gains over 3 and 5 years respectively. Recent coverage around Kinsale Capital Group has focused on...

HF Sinclair recently saw analysts lift their consensus earnings estimate for the March 2026 quarter, anticipating higher year-over-year earnings and revenue, although the report itself now sits in the past relative to today’s date of 27 April 2026. Yet the fact that the Most Accurate Estimate now trails the higher consensus points to a growing split in analyst conviction around HF Sinclair’s near-term profitability. With this backdrop of sharply revised earnings expectations and emerging...

In April 2026, AnaptysBio announced that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim, rejecting Tesaro’s bid to cut Jemperli royalties and affirming that AnaptysBio had not repudiated their Collaboration and Exclusive License Agreement. The ruling removes a key legal challenge to AnaptysBio’s royalty stream while clearing the way for a July 2026 trial on AnaptysBio’s allegations that Tesaro and GSK materially breached the collaboration, including...

In April 2026, Erasca, Inc. announced it had narrowed the anticipated Phase 1 monotherapy data readout window for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 trials to no later than mid-May 2026, from prior guidance of the first half of 2026. This tighter timeline highlights ERAS-0015’s importance within Erasca’s pipeline, as earlier-than-expected visibility on clinical data can influence how investors assess the company’s development progress and clinical risk...